Publications
Page 2 of 2
October 7, 2021
IMM-1-104: a novel, oral, selective dual-MEK inhibitor that displays broad antitumor activity and high tolerability across RAS and RAF mutant tumors in vivo
Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021 Poster #: P252, Presenter: Brett Hall, Ph.D., Immuneering Chief Scientific Officer
Benchmarking the novel dual-MEK inhibitor, IMM-1-104, head-to-head and in combination with sotorasib (AMG-510) in the MIA PaCa-2 (KRAS-G12C) pancreatic cancer xenograft model
Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021 Poster #: P240 Presenter: Peter King, Ph.D., Immuneering Vice President, Head of Discovery
Transcriptional effects in C26 tumor highlight mechanistic aspects of a novel dual MEK inhibitor, IMM-1-104
Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021 Poster #: P254 Presenter: Sarah Kolitz, Ph.D., Immuneering Vice President, Translational Medicine
April 12, 2021
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
Circulating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology, but the accuracy, sensitivity and reproducibility of ctDNA assays is poorly understood. Here we report the findings of…
Journal: Nature Biotechnology
October 12, 2020
Clinical landscape of oncolytic virus research in 2020
Oncolytic viruses (OVs) are a new class of cancer therapeutics. This review was undertaken to provide insight into the current landscape of OV clinical trials. A PubMed search identified 119…
Journal: Journal for ImmunoTherapy of Cancer
May 26, 2020
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune…
Journal: Leukemia
December 12, 2016
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors
Therapeutic drugs that block DNA repair, including poly(ADP-ribose) polymerase (PARP) inhibitors, fail due to lack of tumor-selectivity. When PARP inhibitors and β-lapachone are combined, synergistic antitumor activity results from sustained…
Journal: Cancer Cell
May 22, 2014
BIOMARKERS FOR PREDICTING CLINICAL RESPONSE OF CANCER PATIENTS TO TREATMENT WITH IMMUNOTHERAPEUTIC AGENT
Provided herein are prognostic and diagnostic methods for predicting likelihood of clinical response of a subject having cancer to treatment with an immunotherapeutic agent. Also provided herein are methods for…
Page 2 of 2
